Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
about
Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody propertiesDevelopment of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer.'Image and treat': an individualized approach to urological tumorsIn vivo targeting of HER2-positive tumor using 2-helix affibody molecules.Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expressionAdvancing Molecular-Guided Surgery through probe development and testing in a moderate cost evaluation pipelineAn engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.Novel, cysteine-modified chelation strategy for the incorporation of [M(I)(CO)(3)](+) (M = Re, (99m)Tc) in an α-MSH peptide.Molecular imaging probes for diagnosis and therapy evaluation of breast cancerFeasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.Protein scaffold-based molecular probes for cancer molecular imaging.Clickable, hydrophilic ligand for fac-[M(I)(CO)3](+) (M = Re/(99m)Tc) applied in an S-functionalized α-MSH peptide.Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer.Non-invasive molecular imaging for preclinical cancer therapeutic development.Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.Design and evaluation of radiolabeled tracers for tumor imaging.Antibody mimetics: promising complementary agents to animal-sourced antibodies.Preparation and biological evaluation of 99mTc-HYNIC-(Ser)3-D4 peptide for targeting and imaging of non-small-cell lung cancer.64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragmentDirect comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging.Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging.Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines.Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.Novel Recombinant Traceable c-Met Antagonist-Avimer Antibody Mimetic Obtained by Bacterial Expression Analysis.Antibody Mimetics, Peptides, and Peptidomimetics.Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.Preclinical evaluation of Tc direct labeling Z for HER2 positive tumors imaging
P2860
Q28272997-3DF3CB04-5A3D-4F4F-8CDB-CFBA4DD12B1DQ33649880-C6509CA3-1A5E-4A22-9859-328165DA8A6CQ33792596-53BC0F69-75A6-421D-BDE1-D42D6530FF58Q34231627-57F73C2D-68FD-4BD7-9D4D-5865A27A7BBFQ34996772-714CF189-1F95-4D6B-BFD8-66D21BB5F265Q35518032-8A843CF9-E932-49DC-9350-1696813C6C98Q35583305-195E5E6E-FBC6-44D3-9EA9-B8EFAD1F73C3Q36105964-E189374E-7064-4C82-969D-0C5ACAAD222EQ36476200-621B17DE-B085-49BD-B2B1-CC9216B82887Q36692448-C9D31D3E-A870-45B0-8D57-209B02807C34Q37427038-0FFFB5EC-B24E-485F-92F2-F63E139065DAQ37696357-EF0582EF-7B2B-4998-91FE-8B8863ED1D44Q37697067-E53DEC80-5E8A-4FE1-9404-F4B96E10F341Q38088005-A2509243-061E-4C26-9EDB-F01F1FF792EEQ38089102-D9BE714D-496B-4E2D-A5D9-6B0D7CF6EEE1Q38106992-9C3459CC-8030-4A56-98D3-0957A0CB88B5Q38137253-AA2A74F9-B458-4900-817F-6CD9908A4F5DQ38255176-BE36BD4E-2EE8-497E-9DF0-AA2000B06AF7Q38720107-96F6B291-0A7F-48F9-85B4-AC6C0915A3C2Q38815325-C1EFA12E-A3C9-46CE-9DFD-DA8255C57F90Q39417962-F909D08E-D8BB-475D-8368-E58295618D62Q39428462-4A773026-F95E-4B56-8B18-011EAB9714E0Q39633289-92C04C4D-D8AC-412C-BF54-3A10D5232BD0Q41455532-3B563704-4FEC-4811-BD0C-F46D90F95890Q42018419-152D36DA-D29E-458B-B3D9-CFC777D1FC38Q46219345-F64BE10A-769C-4B4D-B74A-FC4FEF9AE047Q47104185-40C693BE-973C-4648-9386-3FADC2B6DDC7Q50981072-DE6C9098-A1E2-4DBE-892D-86F381ED633EQ55054249-80DCE684-DEB4-4944-AF7B-7B483C08B1E4Q58794885-542EECD3-D034-49AA-9AA4-CE9FFD0722F3
P2860
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@ast
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@en
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@nl
type
label
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@ast
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@en
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@nl
prefLabel
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@ast
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@en
Targeting of HER2-expressing t ...... erminally engineered cysteine.
@nl
P2093
P1476
Targeting of HER2-expressing t ...... terminally engineered cysteine
@en
P2093
Charles Widström
Dietmar Berndorff
Helena Wållberg
Joachim Feldwisch
John E Cyr
Lars Abrahmsén
Ludger M Dinkelborg
Magnus Hjertman
Sara Ahlgren
Thuy A Tran
P304
P356
10.2967/JNUMED.108.056929
P407
P577
2009-04-16T00:00:00Z